MetaCap

IRulya Therapeutics (IRLA) vs Sana Biotechnology (SANA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Sana Biotechnology is the larger company by market cap ($476.4 million vs $432.4 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

IRLA+17.16%SANA-55.21%
+23%-18%-59%
Aug 14, 20261 yearNov 20, 2026
IRLA+17.16%SANA-55.21%
+21%-19%-59%
Aug 10, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

IRLA versus SANA key metrics
MetricIRLASANA
Share price$39.88$1.59
Market cap$432.36M$476.42M
1-day change-0.15%-8.62%
YTD return—-60.93%
1-year return—-51.67%
5-year return—-91.34%
EPS (TTM)$-162.79$-0.52
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-83.98M$-244.17M
52-week high$910.00$5.49
52-week low$15.10$1.57
Distance from 52-week high-95.62%-71.04%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+90.90%+438.99%
Average volume63.03K3.30M
Shares outstanding10.84M299.63M
Employees38142
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About IRulya Therapeutics

IRLA stock →

IRulya Therapeutics Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidate comprises eDSP, which is in Phase 3 for the treatment of rare pediatric neurodegenerative diseases, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in the ATM gene.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 38 employees

About Sana Biotechnology

SANA stock →

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 142 employees

IRLA vs SANA FAQ

Which is bigger, IRulya Therapeutics or Sana Biotechnology?

Sana Biotechnology (SANA) is larger, with a market capitalization of $476.42M compared with $432.36M for IRulya Therapeutics (IRLA).

Are IRulya Therapeutics and Sana Biotechnology in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons